Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.7 USD | +4.40% | +5.47% | -9.57% |
May. 31 | Exelixis Insider Bought Shares Worth $8,733,955, According to a Recent SEC Filing | MT |
May. 20 | Exelixis Settles Cabometyx Patent Litigation with Cipla | MT |
Business Summary
Number of employees: 1,310
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medicines for Difficult-to-treat Cancers
100.0
%
| 1,611 | 100.0 % | 1,830 | 100.0 % | +13.60% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
89.9
%
| 1,414 | 87.8 % | 1,646 | 89.9 % | +16.41% |
Europe
7.9
%
| 169 | 10.5 % | 145 | 7.9 % | -14.01% |
Japan
2.2
%
| 29 | 1.8 % | 39 | 2.2 % | +37.47% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 63 | 00-01-31 | |
Director of Finance/CFO | 56 | 15-07-14 | |
Amy Peterson
CTO | Chief Tech/Sci/R&D Officer | 57 | 23-08-22 |
Dana Aftab
CTO | Chief Tech/Sci/R&D Officer | - | 97-12-31 |
Susan T. Hubbard
IRC | Investor Relations Contact | - | 16-11-30 |
Stefan Krauss
PRN | Corporate Officer/Principal | - | 16-12-06 |
Patrick Haley
PRN | Corporate Officer/Principal | 48 | 09-12-31 |
General Counsel | 55 | 14-02-09 | |
Laura Dillard
HRO | Human Resources Officer | - | 05-10-31 |
Peter Lamb
PRN | Corporate Officer/Principal | 63 | 00-09-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 04-01-31 | |
George Poste
BRD | Director/Board Member | 79 | 04-07-31 |
Founder | 75 | 94-11-14 | |
Chief Executive Officer | 63 | 00-01-31 | |
S. Gail Eckhardt
BRD | Director/Board Member | 66 | Jan. 04 |
Julie Smith
BRD | Director/Board Member | 53 | 16-09-21 |
Mary Beckerle
BRD | Director/Board Member | 69 | Jan. 04 |
Maria Freire
BRD | Director/Board Member | 69 | 18-04-04 |
Tomas Jan Heyman
BRD | Director/Board Member | 68 | 23-05-30 |
Robert Oliver
BRD | Director/Board Member | 65 | 23-05-30 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 291,292,704 | 285,010,771 ( 97.84 %) | 0 | 97.84 % |
Company contact information
Sector
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.57% | 6.32B | |
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- EXEL Stock
- Company Exelixis, Inc.